In conclusion, we have demonstrated that low PNI was significantly correlated with worse survival and a lower treatment response rate, supporting its use as an effective biomarker in SCLC patients treated with PD-L1/PD-1 inhibitors. This evidence concerns the gene PDCD1 and small cell lung carcinoma.